Navigation Links
Healthcare Companies Report Conference Presentation Schedule, Stock Price Updates, and Clinical Study Results - Research Report on Medivation, Envision Healthcare, Fonar, Idera Pharma, and Neurocrine
Date:1/9/2014

NEW YORK, January 9, 2014 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Medivation, Inc. (NASDAQ: MDVN), Envision Healthcare Holdings, Inc. (NYSE: EVHC), Fonar Corp. (NASDAQ: FONR), Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), and Neurocrine Biosciences Inc. (NASDAQ: NBIX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Medivation, Inc. Research Report

On January 6, 2014, Medivation, Inc. (Medivation) announced that it will participate at the upcoming Annual J.P. Morgan Healthcare Conference on January 13, 2014. According to the Company, David Hung, M.D., President and CEO of Medivation, is scheduled to make the presentation on the aforesaid date at 4:30 p.m. PT at the Westin St. Francis Hotel in San Francisco, California. According to the Company, a live audio webcast of the presentation will be made available to interested individuals through Medivation's website. Additionally, Medivation stated that a replay of the webcast will also be made available on the Company's website for 30 days following the live event. The Full Research Report on Medivation, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:  

http://www.analystscorner.com/r/full_research_report/4277_MDVN

Envision Healthcare Holdings, Inc. Research Report

On January 6, 2014, Envision Healthcare Holdings, Inc.'s (Envision Healthcare Holdings) stock advanced by 4.07%, closing the day's trading session at $35.29. In the past three-day trading period, the Company's shares decreased 0.65%, compared to the S&P 500 Index which fell 1.17% over the same trading period. The Full Research Report on Envision Healthcare Holdings, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/4b31_EVHC

Fonar Corp. Research Report

On January 6, 2014, Fonar Corp.'s (Fonar) stock advanced 20.19% to end the day's trading at $23.99. Over the past three-day trading sessions, Fonar's shares reflected an increase of 13.11%, compared to the Dow Jones Industrial Average Index which declined 0.91% during the same three-day trading period. The Full Research Report on Fonar Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/73cc_FONR

Idera Pharmaceuticals, Inc. Research Report

On January 6, 2014, Idera Pharmaceuticals, Inc.'s (Idera Pharmaceuticals) stock gained 1.00%, closing the day at $5.04. During the past three-day trading period, Idera Pharmaceuticals' shares increased 8.86%, compared to the Nasdaq Composite Index which fell 1.51% over the same three-day trading session. The Full Research Report on Idera Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/0b86_IDRA

Neurocrine Biosciences Inc. Research Report

On January 6, 2014, Neurocrine Biosciences Inc. (Neurocrine) announced positive results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study. According to the Company, a small molecule VMAT2 inhibitor, NBI-98854 showed a statistically significant and clinically meaningful reduction in tardive dyskinesia symptoms in the Phase IIb Kinect 2 study. Additionally, Neurocrine stated that the pre-specified primary endpoint was the change-from-baseline in the Abnormal Involuntary Movement Scale (AIMS) at Week 6 as assessed by central blinded video raters. Commenting on the update, Christopher F. O'Brien, Chief Medical Officer of Neurocrine, said, "The profound response in this Kinect 2 study demonstrates the potential of NBI-98854 as both a safe and highly effective treatment for patients suffering from tardive dyskinesia. It is clear from these results that the use of blinded central AIMS raters coupled with the ability to titrate up to 75 mg of NBI-98854 were both critical to the success of this trial." The Full Research Report on Neurocrine Biosciences Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/8228_NBIX

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.AnalystsCorner.com


'/>"/>
SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ProteinSimple to Present at the 32nd Annual J.P. Morgan Healthcare Conference
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Perrigo Company plc To Host Investor Day And To Present At The 32nd Annual J.P. Morgan Healthcare Conference
4. Sangamo BioSciences to Focus on Advancing ZFP Therapeutic Pipeline at J.P. Morgan Healthcare Conference
5. Auxilium Pharmaceuticals, Inc. To Present At The J.P. Morgan 32nd Annual Healthcare Conference
6. Questcor Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
7. SonaCare Medical to Present at the 32nd Annual J.P. Morgan Healthcare Conference
8. Astellas to Present at J.P. Morgan Healthcare Conference
9. Coherus Biosciences Invited to Present at 2014 J.P. Morgan Annual Healthcare Conference
10. Coherus Biosciences als Präsentator zur J.P. Morgan Annual Healthcare Conference 2014 eingeladen
11. SurgiQuest To Present at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... -- M ichael Moore ... Chairman   Mission Therapeutics, a drug discovery and ... treat cancer, neurodegenerative and other diseases, announces that Dr ... January 1 st 2017. Dr Colin Goddard ... in July 2015. Michael Moore , Mission,s Founder Chairman, ...
(Date:12/4/2016)... 3, 2016 Johnson & Weaver, LLP announces that ... of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ) ... 31, 2016 (the "Class Period"). Zimmer Biomet provides ... orthopaedic reconstructive products, such as knee and hip reconstructive products. ... , , ...
(Date:12/4/2016)... , Dec. 3, 2016  Results from the ... SelG1), an anti-P-selectin antibody, reduced the median annual rate ... to placebo (1.63 vs 2.98, p=0.010) in patients with ... that the data are being featured in the official ... of Hematology (ASH) Annual Meeting and presented during the ...
Breaking Medicine Technology:
(Date:12/5/2016)... Lakes, NJ (PRWEB) , ... December 05, 2016 ... ... recording studio teaming up on new songs with prolific Songwriter-Producer Corey “Chorus” Gibson ... Foxx, Kelly Rowland, Ciara, Brandy…just to name a few.     https://twitter.com/coreychorus , ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... moisture measurements are consistently correct. However, regular performance testing is often neglected ... offers a solution: SmartCal™ . This innovative test substance offers a ...
(Date:12/4/2016)... York, NY (PRWEB) , ... December 03, 2016 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – hosted its first Swirl: A Wine Tasting Event in New York ...
(Date:12/4/2016)... ... 04, 2016 , ... "Pro3rd Displace is a set of ... displacement design elements," said Christina Austin - CEO of Pixel Film Studios. ... of design styles that include both left aligned and right aligned options for ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Lori G. ... Traurig, LLP’s Atlanta office, will speak at the American Conference Institute’s 21st Drug ... Traurig is also a Lead Sponsor of the conference. , Cohen, who chairs the ...
Breaking Medicine News(10 mins):